- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06067165
Primary Care Online Emotion-regulation Treatment (POET) (POET)
Mental health problems in youth are a global problem, causing incalculable suffering in youth and families, harming long-term prospects of youths, and creating substantial economic costs to society.
The overall objective of this study is to build an evidence base for a highly scalable transdiagnostic intervention called the Primary care Online Emotion-regulation Treatment (POET) for youth (12-17 years) seeking treatment for mental health problems.
In a randomized controlled trial, the investigators will examine the effects of POET. The investigators will test if emotion regulation mediates reduction in mental health problems during treatment. In addition the investigators will test if POET is more effective for some individuals than others and evaluate if POET is cost-effective. The investigators will also test whether there are detectable effects of POET on distal outcomes utilizing registry data following participants up to 10 years post treatment.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Introduction:
Mental health problems among young people are prevalent and many youth in need of treatment for mental health problems do not meet criteria for any mental health disorder or they meet criteria for several disorders. Most existing treatments focus on a subset of mental disorders and do not address subthreshold or multi-disorder mental health problems. In addition, available treatments do not typically target transdiagnostic disease mechanisms. Furthermore, the available treatments are limited in efficacy and most youth in need do not receive treatment due to social stigma and structural barriers such as geographical distance to treatment providers.
The aim of this randomized clinical trial is to determine the clinical efficacy of a digital emotion regulation treatment in adolescents with mental health problems. Participants will be randomized to a digital emotion regulation treatment or to an active comparator. Treatments in both conditions will include therapist support, and will be delivered in a blended treatment format combining asynchronous therapist-guided online modules with one synchronous session delivered over video-link. The primary endpoint is at post- treatment.
Primary objectives:
- To test the effects of POET on mental health problems.
- To test the effects of POET on emotion regulation.
Secondary objectives:
- To test if emotion regulation mediates reductions in mental health problems during treatment.
- To test if POET is cost-effective.
- To test if POET works better for some individuals than others (i.e., moderation).
- To test if there are detectable differences in distal outcomes between POET and active control 12 to 60 months post treatment and if individual baseline characteristics moderates these effects.
Research questions:
- What are the effects of POET on mental health problems?
- What are the effects of POET on emotion regulation?
- Are reductions in mental health problems during the POET treatment mediated through emotion regulation?
- Is POET feeling cost-effective?
- Does POET work better for some individuals than others?
- Are there detectable differences in distal outcomes between POET and active control 12 to 60 months post treatment and if individual baseline characteristics moderates these effects
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Johan Bjureberg, PhD
- Phone Number: +460852480000
- Email: johan.bjureberg@ki.se
Study Contact Backup
- Name: Katja Sjöblom, MSc
- Phone Number: +460812339504
- Email: katja.sjoblom@ki.se
Study Locations
-
-
-
Stockholm, Sweden, 113 64
- Recruiting
- Karolinska Institutet
-
Contact:
- Johan Bjureberg, PhD
- Phone Number: +46(0)700009188
- Email: johan.bjureberg@ki.se
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age between 12 - 17 years
- Seeking care for mental health problems
- At least one guardian interested in participating in the parent program
- Deemed capable of making decisions
Exclusion Criteria:
- Psychiatric problems that require more extensive treatment.
- Low global functioning (under 41 points on clinician rated C-GAS or functioning that requires more extensive treatment).
- Elevated suicide risk
- Insufficient Swedish comprehension.
- Life circumstances that complicate or make treatment impossible (eg severe deficits in parental care, domestic violence).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: POET feeling
POET will include six guided digital treatment modules for the youth, and six modules for the parents administered over the course of six weeks.
|
POET is adapted from online Emotion Regulation Individual Therapy for Adolescents developed by the research group (ClinicalTrials.gov Identifier: NCT03353961). POET is also based on the Modal model of emotion and Process model of emotion regulation that provides a framework for understanding how emotions are generated, experienced and how they can be regulated. The youth component of POET will include psychoeducation, addressing maladaptive beliefs about emotions and emotion regulation, and teaching adaptive emotion regulation strategies, such as acceptance of emotions and flexible cognitive reappraisal. The parent component will include psychoeducation and teaching effective support and responding to their adolescent's and their own emotions. |
Active Comparator: Supportive treatment
The active control will be supportive treatment.
It includes six guided digital treatment modules for the youth, and six modules for the parents administered over the course of six weeks.
|
The treatment will include educative material on mental health and self-reflection on themes such as school, family and friends.
The parent component will include educative material and self reflection in how to support their adolescent.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Clinical Global Impressions -Severity scale (CGI-S)
Time Frame: Week 0, 7 weeks after treatment start and 3,12 and 60 months after treatment has ended
|
Used to assess symptom severity rated on a single item ranging from 1-7, with higher scores indicating more severe symptoms.
Clinician-rated.
|
Week 0, 7 weeks after treatment start and 3,12 and 60 months after treatment has ended
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Clinical Global Impressions - Improvement scales (CGI-I)
Time Frame: Week 0, 7 weeks after treatment start and 3,12 and 60 months after treatment has ended
|
Used to assess symptom improvement rated on a single item ranging from 1-7, with lower scores indicating more improvement.
Clinician-rated.
|
Week 0, 7 weeks after treatment start and 3,12 and 60 months after treatment has ended
|
The Revised Child Anxiety and Depression Scale-C (RCADS-C)
Time Frame: Week 0, 7 weeks after treatment start and 3,12 and 60 months after treatment has ended
|
Used to assess symptoms of depression and anxiety.
This scale has 47 items, total score ranging from 0 to 141, with higher scores indicating more severe symptoms.
Clinician-rated.
|
Week 0, 7 weeks after treatment start and 3,12 and 60 months after treatment has ended
|
The Revised Child Anxiety and Depression Scale-P (RCADS-P)
Time Frame: Week 0, 7 weeks after treatment start and 3,12 and 60 months after treatment has ended
|
Used to assess symptoms of depression and anxiety in their offspring.
This scale has 47 items, total score ranges from 0 to 141 points, with higher scores indicating more severe symptoms.
Caregiver-reported.
|
Week 0, 7 weeks after treatment start and 3,12 and 60 months after treatment has ended
|
Brief 11-item version of the Revised Child Anxiety and Depression Scale for Adolescents (RCADS-11)
Time Frame: Week 0 and Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7 after treatment start and 3,12 and 60 months after treatment has ended
|
Used to assess symptoms of depression and anxiety in children and adolescents.
This scale has 11 items, total score ranges from 0-33 points, with higher scores indicating more severe symptoms.
Self-rated by adolescents.
|
Week 0 and Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7 after treatment start and 3,12 and 60 months after treatment has ended
|
Children's global assessment scale (CGAS)
Time Frame: Week 0, 7 weeks after treatment start and 3,12 and 60 months after treatment has ended
|
Used to assess global impairment on a single item ranging from 1 to 100, with a higher value indicating better functioning.
Clinician-rated.
|
Week 0, 7 weeks after treatment start and 3,12 and 60 months after treatment has ended
|
The Work and Social Adjustment Scale (WSAS)
Time Frame: Week 0, 7 weeks after treatment start and 3,12 and 60 months after treatment has ended
|
Used to assess impaired functioning in school, everyday life, friends and social life, recreation and hobbies and family and close relationships.
This scale has 5 items, total score ranges from 0 to 40, with higher scores indicating greater impairment.
Clinician-rated.
|
Week 0, 7 weeks after treatment start and 3,12 and 60 months after treatment has ended
|
The Positive and Negative Affect Schedule for Children (PANAS-C)
Time Frame: Week 0 and Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7 after treatment start and 3,12 and 60 months after treatment has ended
|
Used to assess positive and negative feelings.
This scale has 2 subscales.
Each total subscale score range from 5-25, with higher scores indicating more negative or positive feelings.
Self-rated by adolescents.
|
Week 0 and Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7 after treatment start and 3,12 and 60 months after treatment has ended
|
The Emotion Regulation Questionnaire for Children and Adolescents (ERQ-CA)
Time Frame: Week 0 and Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7 after treatment start and 3,12 and 60 months after treatment has ended
|
Used to assess cognitive reappraisal.
The subscale has 6 items, total subscale score ranges from 6-30, with higher scores indicating greater usage of cognitive reappraisal.
Self-rated by adolescents.
|
Week 0 and Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7 after treatment start and 3,12 and 60 months after treatment has ended
|
Difficulties in Emotion Regulation Scale - 16 item version (DERS-16)
Time Frame: Week 0 and Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7 after treatment start and 3,12 and 60 months after treatment has ended
|
Used to assess difficulties in emotion regulation. The scale has 16 items, total score ranges from 16-80, with higher scores indicating more difficulties. Self-rated by adolescents. One subscale named impulse (3 items ranging from 3-15) will be administered once every week during treatment. |
Week 0 and Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7 after treatment start and 3,12 and 60 months after treatment has ended
|
The Process Model of Emotion Regulation Questionnaire -short (PMERQ-S)
Time Frame: Week 0 and Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7 after treatment start and 3,12 and 60 months after treatment has ended
|
Used to assesses individual differences in emotion regulation. This scale has 30 items, total score ranges from 30-180, with higher scores indicate a greater usage of emotion regulation. Self-rated by adolescents. The three subscales named Confront unpleasant situations (3 items, totalt subscale score ranges from 6-18), Avoid unpleasant situations (3 items, totalt subscale score ranges from 6-18) and Cognitively distract (3 items, totalt subscale score ranges 6-18) will administered to adolescents weekly. |
Week 0 and Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7 after treatment start and 3,12 and 60 months after treatment has ended
|
The Perth Alexithymia Questionnaire-Short Form (PAQ-S)
Time Frame: Week 0 and Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7 after treatment start and 3,12 and 60 months after treatment has ended
|
Used to assess alexithymia.
This scale has 6 items, totalt score ranges from 6 to 42, with higher scores indicate higher levels of alexithymia.
Self-rated by adolescents.
|
Week 0 and Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7 after treatment start and 3,12 and 60 months after treatment has ended
|
Self-Efficacy Questionnaire for Children (SEQ-C)
Time Frame: Week 0 and Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7 after treatment start and 3,12 and 60 months after treatment has ended
|
Used to assess social self-efficacy.
The subscale named social self-efficacy has 8 items, total subscale score ranges from 8-40, with higher scores indicating greater social self-efficacy.
Self-rated by adolescents.
|
Week 0 and Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7 after treatment start and 3,12 and 60 months after treatment has ended
|
Child Health Utility 9D (CHU-9D)
Time Frame: Week 0, 7 weeks after treatment start and 3,12 and 60 months after treatment has ended
|
Used to assess health-related quality of life.
This scale has 9 items, total score ranges from 9 to 45, with higher scores indicating worse quality of life.
Self-rated by adolescents.
|
Week 0, 7 weeks after treatment start and 3,12 and 60 months after treatment has ended
|
Borderline symptoms checklist supplement (BSL-23)
Time Frame: Week 0, 7 weeks after treatment start and 3,12 and 60 months after treatment has ended
|
Used to assess high-risk and problematic behaviors.
This scale has 10 items, total score ranges from 0 to 40, with higher scores indicating greater usage of high-risk and problematic behaviors.
Self-rated by adolescents.
|
Week 0, 7 weeks after treatment start and 3,12 and 60 months after treatment has ended
|
The Emotion Beliefs Questionnaire (EBQ)
Time Frame: Week 0, 7 weeks after treatment start and 3,12 and 60 months after treatment has ended
|
Used to assess beliefs about emotions.
This scale 16 items, total score ranges from 16 to 112, with higher scores indicating more maladaptive beliefs about emotions.
Self-rated by adolescents.
|
Week 0, 7 weeks after treatment start and 3,12 and 60 months after treatment has ended
|
Coping with Children's Negative Emotions Scale Adolescent Version (CCNES-A)
Time Frame: Week 0, 7 weeks after treatment start and 3,12 and 60 months after treatment has ended
|
Used to assess parents' perceived ability to cope with children's negative emotions.
This scale has six subscales which include emotion focused, problem-focused, minimization, punitive, expressive encouragement, and distress responses.
Each subscale has 9 items, total subscale score ranges from 1-7, with higher scores indicating greater usage of a certain parental coping style.
Care-giver reported.
|
Week 0, 7 weeks after treatment start and 3,12 and 60 months after treatment has ended
|
Difficulties in Emotion Regulation Scale - 16 item version (DERS-16)
Time Frame: Week 0, 7 weeks after treatment start and 3,12 and 60 months after treatment has ended
|
Used to assess difficulties in emotion regulation.
The scale has 16 items, total score ranges from 16-80, with higher scores indicating more difficulties.
Self-rated by parents.
|
Week 0, 7 weeks after treatment start and 3,12 and 60 months after treatment has ended
|
Behavioral emotion regulation questionnaire (BERQ)
Time Frame: Week 0, 7 weeks after treatment start and 3,12 and 60 months after treatment has ended
|
Used to assess parents' perception of the adolescent's behavioral emotion regulation.
This scale has 5 subscales.
Each total subscale score ranges from 4-20, with higher scores indicating greater usage of a certain strategy.
Care-giver reported.
|
Week 0, 7 weeks after treatment start and 3,12 and 60 months after treatment has ended
|
Trimbos Questionnaire for Costs associated with Psychiatric Illness (TiC-P)
Time Frame: Week 0, 7 weeks after treatment start and 3,12 and 60 months after treatment has ended
|
Used to assess healthcare and other societal resource use for both children and caregivers.
Caregiver-reported.
|
Week 0, 7 weeks after treatment start and 3,12 and 60 months after treatment has ended
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Credibility/Expectancy Questionnaire (CEQ)
Time Frame: Week 0 and Week 1, Week 2, Week 3, Week 4, Week 5, Week 6 after treatment start.
|
Used to assess treatment credibility and expectancy.
The scale has 5 items ranging from 4-58 with higher scores indicating greater credibility/expectancy.
Clinician-reported, adolescents self-rated, care-giver reported.
|
Week 0 and Week 1, Week 2, Week 3, Week 4, Week 5, Week 6 after treatment start.
|
Client Satisfaction Questionnaire (CSQ)
Time Frame: 7 weeks after treatment start
|
Used to assess client satisfaction with treatment.
This scale has 8 items ranging from 8-32 points with higher scores indicating greater treatment satisfaction.
Adolescents self-rated, care-giver reported.
|
7 weeks after treatment start
|
Patient Internet Cognitive behavior therapy Adherence Scale (PIAS)
Time Frame: 3 and 7 weeks after treatment start
|
Used to assess patient adherence to internet-delivered behavioral interventions.
This scale has 5 items, total score ranging from 0 to 20, where 0 indicates no adherence and 20 perfect adherence.
Clinician-rated.
|
3 and 7 weeks after treatment start
|
Questionnaire on Adverse events
Time Frame: 7 weeks after treatment start
|
Used to assess adverse events related to treatment.
Adolescents are asked to report any negative effects or adverse events throughout the treatment period.
Adolescents are also requested to report the extent of the impact of any potential adverse events on their well-being using a 0-4 scale, with a higher score indicating a more significant impact.
Adolescent self-reported.
|
7 weeks after treatment start
|
Academic performance
Time Frame: 5 years after after treatment has ended
|
Grades in school using data from the Swedish registry Longitudinal Integration Database for Health Insurance and Labour Market Studies (LISA).
|
5 years after after treatment has ended
|
Occupation
Time Frame: 5 years after after treatment has ended
|
Unemployment rates using data from the Swedish registry Longitudinal Integration Database for Health Insurance and Labour Market Studies (LISA) that contains information on occupation.
|
5 years after after treatment has ended
|
Health-care consumption
Time Frame: 5 years after after treatment has ended
|
Number of health care visits using data from the National (Sweden) Patient Register.
|
5 years after after treatment has ended
|
Psychopharmacological treatment
Time Frame: 5 years after after treatment has ended
|
Number of psychotropic medications using data from National (Sweden) Prescribed Drug Register.
|
5 years after after treatment has ended
|
Mental health disorders
Time Frame: 5 years after after treatment has ended
|
Number of mental disorders according to the ICD-10 and ICD-11 using data from the National (Sweden) Patient Register.
|
5 years after after treatment has ended
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Johan Bjureberg, Karolinska Institutet
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2023-03652-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mental Health Issue
-
King's College LondonCompletedMental Health Wellness 1 | Mental Health IssueUnited Kingdom
-
Hospices Civils de LyonNot yet recruiting
-
The Hong Kong Polytechnic UniversityRecruiting
-
Stanford UniversityNot yet recruitingMental Health Issue
-
The Hong Kong Polytechnic UniversityRecruiting
-
Weill Medical College of Cornell UniversityDoris Duke Charitable FoundationNot yet recruiting
-
Yale UniversityEmpowerment to Heal - Uganda; Empower Through HealthRecruiting
-
The Hong Kong Polytechnic UniversityRecruiting
-
Dr. Nazanin AlaviWithdrawnMental Health IssueCanada
-
Northwestern UniversityWithdrawnMental Health IssueUnited States
Clinical Trials on POET feeling
-
Ruhr University of BochumCompletedMental Health | Positive EmotionsGermany
-
Sprim Advanced Life SciencesArtsana S.p.a.CompletedFeeding Behavior
-
St. Antonius HospitalNot yet recruitingErectile Dysfunction | Erectile Dysfunction Following Radical ProstatectomyNetherlands
-
St. Antonius HospitalCompletedErectile DysfunctionNetherlands
-
Royal Free Hospital NHS Foundation TrustUniversity College, LondonUnknownDepressive Disorder | Covid19 | Anxiety Disorders | Post Traumatic Stress Disorder
-
University of California, IrvineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
St. Antonius HospitalCompletedErectile DysfunctionNetherlands
-
Fundacio Salut i Envelliment UABRecercaixa; Equip Atencio Primaria SardenyaCompletedAging | Self Care | Health Literacy | Social Capital | Subjective Health | Health Status Disparities
-
The University of Hong KongSydney Children's Hospitals Network; SAHKRecruitingAutism Spectrum DisorderHong Kong
-
Duke UniversityNational Institute of Mental Health (NIMH)Active, not recruitingARFID | Picky Eating | Eating Disorders in ChildrenUnited States